Work

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-123405

Authors: Melody Luo, Dolly A. Parasrampuria, Saad Z. Usmani, Maria-Victoria Mateos, Hareth Nahi, Christoph Heuck, Ming Qi, Steven Sun, Pamela L. Clemens, Honghui Zhou, Yu-Nien (Tom) Sun, Steven Xu

Institutions: Levine Cancer Institute, Instituto de Investigación Biomédica de Salamanca, Karolinska University Hospital, Karolinska Institutet, Janssen Research & Development (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2986137913

Cites:

Cited by:

Related to: 10